Company
Vision: We are a pioneer in providing innovative treatments, advanced diagnostics, and education aimed at improving the quality of life for allergy patients
DIATER Group
DIATER, founded in 1999 in Madrid, develops innovative allergy diagnostics and treatments. It pioneered molecular immunotherapies for key allergens and offers personalized therapies for complex allergies. With international expansion, it remains committed to improving patients' lives.
DIATER Group is composed of DIATER Laboratories (with 3 entities in Spain, Portugal and Germany) and Allergen Servilab in Spain. In 2023 DIATER Group was acquired by the Chinese company WORG Pharmaceuticals, a strategic clinical stage biopharmaceutical company, with an international executive committee, investing in innovative companies developing new treatments for allergic and autoimmune diseases.
Ethical and sustainability commitment
DIATER is a biopharmaceutical company dedicated to the development and manufacture of diagnostics and treatments for allergy patients. The development of a quality product is ensured by rigorous manufacturing control, from the selection of raw materials to the final product. DIATER's commitment to innovation and research allows us to develop innovative products for the allergy patient.
Since its foundation, DIATER has always been committed to innovation, quality and transparency in allergy care.
Innovation
Our first class R&D facilities, together with collaborations with leading Spanish and international distinguished research groups, provide the company with an outstanding innovative capacity.
At DIATER, we take pride in leading advancements in the field of allergies and pioneering the development of diverse solutions adapted to the patients needs. Our commitment to innovation is demonstrated through the continuous introduction of new products, translating our research achievements into practical applications for allergology.
Commitment to quality
Coordination and teamwork between the R&D department and the manufacturing plant guarantee the success and efficiency of the production processes. DIATER products are the result of a deep knowledge of allergenic extracts, a constant application of the most innovative techniques and a rigorous manufacturing process, in compliance with the Good Manufacturing Practice (GMP) for medicines. All this is the result of a strong commitment to the quality of the products offered to patients.
Transparency
DIATER strives to establish a relationship of trust between the pharmaceutical and healthcare sectors. It works to create a transparent environment, based on a relationship of the utmost respect between DIATER employees, healthcare professionals and patients. This transparency is based on strict compliance with all the regulations of the pharma industry code, to which it belongs, together with adherence to all the relevant legal regulations.